Sensei Biotherapeutics (NASDAQ:SNSE) Lifted to Buy at Zacks Investment Research

Sensei Biotherapeutics (NASDAQ:SNSEGet Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Tuesday, reports. The brokerage currently has a $1.75 price objective on the stock. Zacks Investment Research‘s target price points to a potential upside of 1.74% from the company’s previous close.

According to Zacks, “Sensei Biotherapeutics Inc. is a clinical-stage immunotherapy company. It is focused on the discovery and development of therapeutics for cancer. The company’s product pipeline includes SNS-301, SNS-401 and SNS-VISTA. Sensei Biotherapeutics Inc. is based in BOSTON, Md. “

Separately, Piper Sandler dropped their price target on shares of Sensei Biotherapeutics from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Thursday, March 10th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $10.96.

NASDAQ:SNSE traded up $0.07 during midday trading on Tuesday, reaching $1.72. 2,010 shares of the stock traded hands, compared to its average volume of 78,833. The company has a debt-to-equity ratio of 0.01, a quick ratio of 18.27 and a current ratio of 18.27. Sensei Biotherapeutics has a 12 month low of $1.45 and a 12 month high of $14.02. The stock has a market capitalization of $52.68 million, a P/E ratio of -1.31 and a beta of 0.79. The company has a fifty day moving average of $2.00 and a 200 day moving average of $4.31.

Sensei Biotherapeutics (NASDAQ:SNSEGet Rating) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.05). On average, analysts predict that Sensei Biotherapeutics will post -1.64 EPS for the current fiscal year.

In other Sensei Biotherapeutics news, Director James Peyer acquired 15,000 shares of the stock in a transaction dated Thursday, February 24th. The shares were purchased at an average price of $3.63 per share, for a total transaction of $54,450.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders bought a total of 21,203 shares of company stock worth $76,800 in the last quarter.

Several large investors have recently modified their holdings of SNSE. Citigroup Inc. raised its stake in Sensei Biotherapeutics by 565.5% during the 3rd quarter. Citigroup Inc. now owns 2,409 shares of the company’s stock worth $25,000 after acquiring an additional 2,047 shares during the period. Royal Bank of Canada lifted its position in shares of Sensei Biotherapeutics by 255.1% during the third quarter. Royal Bank of Canada now owns 2,411 shares of the company’s stock worth $25,000 after purchasing an additional 1,732 shares during the last quarter. Morgan Stanley bought a new stake in shares of Sensei Biotherapeutics in the first quarter valued at about $96,000. Wells Fargo & Company MN raised its holdings in shares of Sensei Biotherapeutics by 14,298.4% in the fourth quarter. Wells Fargo & Company MN now owns 8,783 shares of the company’s stock valued at $51,000 after acquiring an additional 8,722 shares in the last quarter. Finally, Jane Street Group LLC bought a new position in Sensei Biotherapeutics in the first quarter worth about $25,000. Hedge funds and other institutional investors own 11.10% of the company’s stock.

Sensei Biotherapeutics Company Profile (Get Rating)

Sensei Biotherapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways.

Further Reading

Get a free copy of the Zacks research report on Sensei Biotherapeutics (SNSE)

For more information about research offerings from Zacks Investment Research, visit

Analyst Recommendations for Sensei Biotherapeutics (NASDAQ:SNSE)

Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with's FREE daily email newsletter.